Abstract
Relevance. Drug-associated osteonecrosis is known to cause some pathological changes. The titers of biomarkers responsible for bone metabolism are also subject to such changes. They are essential in the diagnosis and treatment planning, especially during surgical interventions, because of the risk of osteonecrosis. Purpose – based on the data of modern scientific literature and articles, identifying markers of bone remodeling and endothelial disorders is of primary importance for optimizing the early diagnosis of microcirculati on disorders in patients with maxillofacial pathologies.Materials and methods. A review of available data in the literature on normal bone anatomy, bone biomarkers, and regulatory factors. The study of diagnostic modes and identification of the most valuable and fastest in bone and vascular endothelium impairment.Results. According to the studies, osteocalcin, C-terminal telopeptide, tartrate-resistant acid phosphatase and VEGF are clinically the most informative for predicting jawbone osteonecrosis. With a serum C-terminal telopeptide concentration of less than 100 pg/mL, the risk of osteonecrosis increases. Serum osteocalcin is a specific biomarker of osteoblast function for assessing the rate of bone formation in osteoporosis. The average osteocalcin level revealed a significant difference between postmenopausal osteoporotic (16.16 ± 4.5 ng/ml) and non-osteoporotic (11.26 ± 3.07 ng/ml) women. Tartrate-resistant acid phosphatase (TRAP 5b) is used to reference the activity and number of osteoclasts. TRAP 5b can be specifically detected in serum by immunoassays.Conclusion. The study of bone degeneration markers and vascular markers allows us to understand the principles of the occurrence of osteonecrosis more clearly, and, therefore, more clearly predict, diagnose osteonecrosis, and also correctly select the tactics of treatment for these patients, the type of surgical intervention, conservative, operative (partial resection, total jaw resection), – palliative, pre- and post-drug preparation of the body for intervention.
Highlights
Санкт-Петербург, Российская Федерация 2Городской клинический онкологический диспансер, Санкт-Петербург, Российская Федерация Резюме Актуальность
The average osteocalcin level revealed a significant difference between postmenopausal osteoporotic (16.16 ± 4.5 ng/ml) and non-osteoporotic (11.26 ± 3.07 ng/ml) women
TRAP 5b can be detected in serum by immunoassays
Summary
Маркеры Markers Остеонектин, костный сиалопротеин, остеокальцин N-MID, остеопонтин, С-концевой пропептид проколлагена типа 1 (P1CP), N-концевой пропептид проколлагена типа 1 (P1NP) Osteonectin, Bone Sialoprotein, Osteocalcin N-MID, Osteopontin, C-Terminal Type 1 Procollagen Propeptide (P1CP), N-Terminal Type 1 Procollagen Propeptide (P1NP) N-терминальный телопептид, коллагена 1 типа (NTX), C-terminal teloprptide коллагена 1 типа (CTX), pyridinoline (PYD), гидроксипролин, костный cиалопротеин, тартрат-нечувствительная фосфатаза 5b, остеокальцин N-MID, 1,25-гидроксивитамин D3 N-terminal telopeptide, collagen type 1 (NTX), C-terminal teloprptide type 1 collagen (CTX), pyridinoline (PYD), Hydroxyproline, Bone sialoprotein, Tartrate insensitive phosphatase 5b, Osteocalcin N-MID, 1,25-hydroxyvitamin D3 RANK/RANKL/OPG, TGF b, простагландин E2, остеопротегерин OPG, RANKL RANK / RANKL / OPG, TGF b, Prostaglandin E2, Osteoprotegerin OPG, RANKL
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.